{
     "PMID": "26707399",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20170124",
     "LR": "20170805",
     "IS": "1464-3405 (Electronic) 0960-894X (Linking)",
     "VI": "26",
     "IP": "2",
     "DP": "2016 Jan 15",
     "TI": "Preclinical characterization of substituted 6,7-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-8(5H)-one P2X7 receptor antagonists.",
     "PG": "257-261",
     "LID": "S0960-894X(15)30365-6 [pii] 10.1016/j.bmcl.2015.12.052 [doi]",
     "AB": "The synthesis, SAR, and preclinical characterization of a series of substituted 6,7-dihydro[1,2,4]triazolo[4,3]pyrazin-8(5H)-one P2X7 receptor antagonists are described. Optimized leads from this series comprise some of the most potent human P2X7R antagonists reported to date (IC50s<1nM). They also exhibit sufficient potency and oral bioavailability in rat to enable extensive in vivo profiling. Although many of the disclosed compounds are peripherally restricted, compound 11d is brain penetrant and upon oral administration demonstrated dose-dependent target engagement in rat hippocampus as determined by ex vivo receptor occupancy with radiotracer 5 (ED50=0.8mg/kg).",
     "CI": [
          "Copyright (c) 2015 Elsevier Ltd. All rights reserved."
     ],
     "FAU": [
          "Ameriks, Michael K",
          "Ao, Hong",
          "Carruthers, Nicholas I",
          "Lord, Brian",
          "Ravula, Suchitra",
          "Rech, Jason C",
          "Savall, Brad M",
          "Wall, Jessica L",
          "Wang, Qi",
          "Bhattacharya, Anindya",
          "Letavic, Michael A"
     ],
     "AU": [
          "Ameriks MK",
          "Ao H",
          "Carruthers NI",
          "Lord B",
          "Ravula S",
          "Rech JC",
          "Savall BM",
          "Wall JL",
          "Wang Q",
          "Bhattacharya A",
          "Letavic MA"
     ],
     "AD": "Janssen Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, CA 92121, United States. Janssen Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, CA 92121, United States. Janssen Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, CA 92121, United States. Janssen Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, CA 92121, United States. Janssen Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, CA 92121, United States. Janssen Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, CA 92121, United States. Janssen Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, CA 92121, United States. Janssen Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, CA 92121, United States. Janssen Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, CA 92121, United States. Janssen Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, CA 92121, United States. Janssen Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, CA 92121, United States.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article"
     ],
     "DEP": "20151217",
     "PL": "England",
     "TA": "Bioorg Med Chem Lett",
     "JT": "Bioorganic & medicinal chemistry letters",
     "JID": "9107377",
     "RN": [
          "0",
          "(7-(2-chloro-3-(trifluoromethyl)benzyl)-6-methyl-3-pyrimidin-2-yl-6,7-dihydro(1,2",
          ",4)triazolo(4,3-a)pyrazin-8(5H)-one)",
          "0 (Central Nervous System Agents)",
          "0 (Purinergic P2X Receptor Antagonists)",
          "0 (Pyrazines)",
          "0 (Receptors, Purinergic P2X7)",
          "0 (Triazoles)",
          "10028-17-8 (Tritium)"
     ],
     "SB": "IM",
     "MH": [
          "Animals",
          "Blood-Brain Barrier/metabolism",
          "Caco-2 Cells",
          "Central Nervous System Agents/chemical synthesis/pharmacokinetics/*pharmacology",
          "Hippocampus/metabolism",
          "Humans",
          "Microsomes, Liver/metabolism",
          "Purinergic P2X Receptor Antagonists/chemical synthesis/pharmacokinetics/*pharmacology",
          "Pyrazines/chemical synthesis/pharmacokinetics/*pharmacology",
          "Rats",
          "Receptors, Purinergic P2X7/metabolism",
          "Stereoisomerism",
          "Structure-Activity Relationship",
          "Triazoles/chemical synthesis/pharmacokinetics/*pharmacology",
          "Tritium"
     ],
     "OTO": [
          "NOTNLM"
     ],
     "OT": [
          "6,7-Dihydro-[1,2,4]triazolo[4,3-a]pyrazin-8(5H)-one",
          "Autoradiography",
          "CNS",
          "Depression",
          "P2X7"
     ],
     "EDAT": "2015/12/29 06:00",
     "MHDA": "2017/01/25 06:00",
     "CRDT": [
          "2015/12/29 06:00"
     ],
     "PHST": [
          "2015/11/05 00:00 [received]",
          "2015/12/12 00:00 [revised]",
          "2015/12/15 00:00 [accepted]",
          "2015/12/29 06:00 [entrez]",
          "2015/12/29 06:00 [pubmed]",
          "2017/01/25 06:00 [medline]"
     ],
     "AID": [
          "S0960-894X(15)30365-6 [pii]",
          "10.1016/j.bmcl.2015.12.052 [doi]"
     ],
     "PST": "ppublish",
     "SO": "Bioorg Med Chem Lett. 2016 Jan 15;26(2):257-261. doi: 10.1016/j.bmcl.2015.12.052. Epub 2015 Dec 17.",
     "term": "hippocampus"
}